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Background: Cerebral stroke is a severe and frequent condition that requires rapid and reliable diagnosis. If
administered shortly after the first symptoms manifest themselves, IV thrombolysis has been shown to increase
the functional prognosis by restoring brain reperfusion. However, a better understanding of the pathophysiology
of stroke should help to identify potential new therapeutic targets. Stroke is known to induce an inflammatory
brain reaction that involves overexpression of the 18-kDa translocator protein (TSPO) in glial cells and infiltrated
leukocytes, which can be visualised by positron emission tomography (PET). We aimed to evaluate post-stroke
neuroinflammation using the PET TSPO radioligand 18 F-DPA-714.
Methods: Nine patients underwent 18 F-DPA-714 PET and magnetic resonance imaging (MRI) between 8 and
18 days after the ictus. Co-registration of MRI and PET images was used to define three volumes of interest (VOIs):
core infarction, contralateral region, and cerebellum ipsilateral to the stroke lesion. Time activity curves were
obtained from each VOI, and ratios of mean and maximum activities between the VOIs were calculated.
Results: We observed an increased uptake of 18 F-DPA-714 co-localised with the infarct tissue and extension
beyond the region corresponding to the damage in the blood brain barrier. No correlation was identified between
18 F-DPA-714 uptake and infarct volume. 18 F-DPA-714 uptake in ischemic lesion (mainly associated with TSPO
expression in the infarct area and in the surrounding neighbourhood) slowly decreased from 10 min pi to the end
of the PET acquisition, remaining higher than that in both contralateral region and ipsilateral cerebellum.
Conclusion: Our results show that 18 F-DPA-714 uptake after acute ischemia is mainly associated with TSPO expression
in the infarct area and in the surrounding neighbourhood. We also demonstrated that the kinetics of 18 F-DPA-714
differs in injured tissue compared to normal tissue. Therefore, 18 F-DPA-714 may be useful in assessing the extent of
neuroinflammation associated with acute stroke and could also help to predict clinical outcomes and functional
recovery, as well as to assess therapeutic strategies, such as the use of neuroprotective/anti-inflammatory drugs.
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Cerebral stroke is a severe and frequently occurring
condition that represents a leading cause of mortality
and morbidity worldwide [1,2], being also the main
aetiology of adult-acquired disabilities [3,4]. Stroke is
haemorrhagic in 10% to 15% of cases but more often
it is ischemic (85% to 90%) [3]. Due to arterial occlusion,
ischemic stroke is a diagnostic and therapeutic priority;* Correspondence: maria.ribeiro@univ-tours.fr
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in any medium, provided the original work is pemergency treatment (e.g., intravenous thrombolysis)
should be administered in the first hours after symptom
onset. Unfortunately, no other emergency drug treatment
has been validated, but an improved understanding of the
pathophysiology of early cerebral ischemia should identify
potential molecular targets, particularly for neuroprotective
treatments. Therefore, promising neuroprotective drugs,
which demonstrated effectiveness in animals, have been
evaluated; however, these results remain unconfirmed in
clinical trials [5,6]. Moreover, there is a lack of reliable
imaging strategies to assess brain neuroinflammation
after stroke [7-9].an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Clinical characteristics of the patients included in
the study









1 F Right MCA 82 73 14
2 M Left MCA 55 88 11
3 F Right MCA 71 94 13
4 F Left MCA 82 62 13
5 M Right MCA 71 68 12
6 M Right MCA 63 97 8
7 F Right MCA 77 53 11
8 M Left MCA 56 54 13
9 F Right MCA 58 62 18
MCA, middle cerebral artery.
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peri-necrosis area of ischemic penumbra, in which the
brain tissue is still viable for a few hours. This cerebral
tissue can be preserved if treatment is initiated quickly to
restore the cerebral blood flow. Thus, this area of ‘darkness’
is the prime target for potential neuroprotective drugs. In
animals, the infarcted area has been shown to expand in
24 h after the occlusion of a cerebral artery [10,11].
Although different mechanisms are involved in the
pathogenesis of stroke, increasing evidence suggests
that inflammation, mainly involving the microglial
and the immune system cells, account for its pathogenic
progression [11].
Experimental studies have demonstrated that microglial
cells are the first inflammatory cells activated after the
onset of cerebral ischemia [12]. After breakdown of the
blood-brain barrier (BBB), which accompanies cerebral
ischemia, the perivascular microglia and macrophages are
activated; this activation appears to be at least partially
responsible for the inflammatory lesions in cerebral
infarctions [12]. Microglia, which constitute up to
10% of the total brain cell population, change from a
resting to an activated state in response to central
nervous system insults, and this change stimulates
these cells for phagocytosis. Several studies focusing on
the inflammatory reaction during the first days after
stroke have demonstrated that this inflammatory response
changes dramatically over time [13,14]. Therefore, the
inflammatory markers correlated to the time course must
be considered for any anti-inflammatory treatment
approach in patients with acute ischemic strokes [14].
In humans, microglial activation can be assessed in vivo
through neuroimaging of the 18-kDa translocator protein
(TSPO) with selective TSPO radioligands. TSPO, formerly
known as peripheral benzodiazepine receptor (PBR), is
part of a multimeric ‘protein complex’ associated with the
outer mitochondrial membrane of many cells [15]. TSPO
is present in peripheral tissues and also in glial cells, but
in the healthy brain, its expression is minimal [16]. TSPO
may therefore be a valuable biomarker of inflammation, as
it is highly expressed in phagocytic inflammatory cells.
A large number of positron emission tomography (PET)
and single photon emission computerised tomography
(SPECT) radioligands, selective for TSPO, have been devel-
oped, of which 11C-PK11195 was the first to be evaluated
[17]. Studies using 11C-PK11195 demonstrated increased
binding of this radiotracer around the outer border of
ischemic lesions several days after stroke, as well as in dis-
tant areas from the lesion [18-23]. This increased uptake
was observed from 3 days after ictus, reaching its max-
imum at 7 days, and continuing for a period of 4 weeks [9].
However, the 20-min radioactive half-life of 11C-PK11195
is a serious drawback to the increased accessibility of
biomarkers for routine clinical purposes since the useof these markers is limited to centres with an on-site
cyclotron. Fluorine-18-labelled ligands, therefore, appear to
be the best alternative, as the 110-min half-life of fluorine-
18 enables centralised production and loco-regional deliv-
ery. Several groups have also evaluated neuroinflammation
models in rats using the TSPO radioligand 18 F-DPA-714,
concluding that it provides accurate quantitative informa-
tion of TSPO density after cerebral ischemia, herpes
encephalitis, amyotrophic lateral sclerosis, and gliomas
[24-27]. Several studies have already demonstrated
that the regional distribution of 18 F-DPA-714 aligned
well with other PET studies using TSPO radioligands
in the human brain [25,26].
The aim of the present study was to assess microglial
activation after a recent stroke using 18 F-DPA-714, and to
evaluate the relationship between 18 F-DPA-714 uptake




This study was approved by the local Medical Bioethics
Committee and was conducted according to French
legislation and European directives.
Nine patients (Table 1) with recent unilateral cerebral
infarcts were included. All patients underwent MRI and
PET brain scans, with a maximum interval of 24 h between
the two acquisitions. The following inclusion criteria were
applied: Patients aged between 18 and 85 years, with a
recent cerebral infarct involving the medial cerebral artery,
visualised on computed tomography (CT) or MRI images,
6 to 20 days before the PET examination. None of the
patients received the thrombolytic treatment, and none
showed any symptoms suggesting the presence of any other
significant neurodegenerative or psychiatric disease or had
severe renal insufficiency, contraindicating the injection of
a gadolinium chelate. No subject had been treated with
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study or with drugs that might interfere with 18 F-DPA-714
binding. All patients provided informed written consent
before participating in the study.Radiosynthesis
N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethyl-
pyrazolo[1,5-α]pyrimidin-3-yl)acetamide (DPA-714) was
labelled with fluorine-18 at its 2-fluoroethyl moiety,
following nucleophilic substitution of the corresponding
tosylate analogue, according to slight modifications of
previously reported procedures [28]. The formulation
of 18 F-DPA-714 provided a sterile injectable solution of
isotonic sodium chloride with ethanol at a mass percentage
of <8% for total injected volumes (ranging from 3 to 5 mL),
in accordance with the European Pharmacopoeia. The
mean specific activity of 18 F-DPA-714 obtained was
113.9 ± 36.9 GBq/μmol.Imaging data acquisition
Brain MRI studies were performed using a 1.5 T imager
(GE Healthcare, Milwaukee, WI, USA). Diffusion, FLAIR
T2, T2*-weighted GRE sequences and high-resolution
T1-weighted 3D MRI volumes were acquired for all
subjects before and after the gadolinium administra-
tion (Gadobenate dimeglumine, Bracco imaging®, Ceriano
Laghetto, Italy).
FLAIR T2-weighted and diffusion-weighted images
showed the extent of cerebral infarction, whereas the
T1-weighted SPGR image was used to allow co-registration
with the PET images. After the gadolinium injection, axial
volumetric T1 acquisition was performed to clarify the
extent of the BBB breakdown.
PET studies were performed using a Dual Gemini
(Philips Medical Systems, Amsterdam, the Netherlands),
a whole-body hybrid PET/CT scanner with a full-width-
half-maximum (FWHM) resolution of 5 mm in all direc-
tions, in 3D acquisition mode. To perform attenuation
correction, a low dose CT helical scan was done
(scan field, 600 mm; increments, 5 mm; slice thickness,
3.2 mm; pitch, 1.5, 0.75 second per rotation; 512 × 512
matrix; 120 kV; 80 mAs). Acquisition data were recon-
structed with the standard package included with the
system (PET view software-Philips Medical Systems). PET
sinograms were corrected for tissue attenuation, decay,
scatter, and random radiation, and then they were recon-
structed using a 3D iterative RAMLA algorithm in voxels
of 2 × 2 × 2 mm3.
To limit incidental movement, the patient's head was
positioned in a headrest using a 3D laser alignment. All
cerebral PET examinations were acquired in list mode
over 90 min, after IV injection of 244.0 ± 27.4 MBq
of 18 F-DPA-714.Data analysis
An integrated PET image was obtained for each subject
from the 90-min acquisition. This image was used to
perform co-registration with each corresponding MRI
image (T1-weighted SPGR and post-contrast images).
Non-rigid registration was performed using normalised
mutual information and PMOD® 3.4 software.
For each subject, a volume of interest (VOI) was
defined over the injured tissue (IT) using individual MRI
images. A similar VOI was transposed according to the
region on the contralateral (CL) unaffected hemisphere.
A VOI was also defined over the ipsilateral cerebellum
to the injured tissue. All of VOIs were transposed onto
PET images to obtain time activity curves (TACs). TACs
were used to evaluate the kinetics of 18 F-DPA-714 over
the 90-min acquisition. Ratios between the mean activity
of the injured tissue VOIs and the contralateral (IT/CL)
and cerebellar (IT/C) VOIs were calculated. We also
determined similar ratios using the maximal activity
measured in the same VOI.
For the nine patients, the infarct volumes (cm3) were
calculated using the corresponding MRI images. Infarct
volumes were manually outlined on diffusion-weighted
MR images by an experienced neuroradiologist using an
imaging analysis tool (functool, advantage windows,
version 4.3; GE healthcare).
Statistical analysis
All data are presented as the mean ± standard deviation
of the mean (SD). Significance was set at p < 0.05.
Wilcoxon signed-rank test for paired values was used
to determine the significant difference between VOIs
ratios. Spearman's correlation test was used to assess
the relationship between the volume of the lesion and
18 F-DPA-714 uptake ratios and between lesion volume
measured by MRI and PET.
Results
The patients' clinical characteristics are summarised in
Table 1. No adverse or subjective effects were observed for
any of the nine subjects studied after injecting an average
of 244.0 ± 27.4 MBq of 18 F-DPA-714. The imaging studies
were performed 12.6 ± 2.7 days (min 8 days, max 18 days)
after the acute injury.
Figure 1 shows an example of MRI and 18 F-DPA-714
images obtained from one patient (patient 4). For this
patient, we observed that the radiopharmaceutical
uptake is relatively comparable to injury tissue highlighted
by MRI.
Figure 2 depicts a representative TAC of 18 F-DPA-714
uptake in the injured tissue and in the intact counterpart
contralateral region and ipsilateral cerebellum (both used
as reference regions) from a single subject. Figure 3 shows
the evolution of the ratios calculated between the mean
Figure 1 Axial images obtained after vascular injury. The imaging studies were performed 13 days post-stroke. The infarct volume evaluated
on MRI was 13 cm3. (A) Flair T2-weighted MR image. Left fronto-insular hypersignal demonstrating infarcted tissue. (B) Post-gadolinium T1-weighted
MR image. Enhancement signal in the left fronto-insular cortex corresponding to the breakdown of BBB. (C) Co-registration image obtained between
the post-gadolinium T1 MRI and PET. Note the absence of 18 F-DPA-714 uptake by the multiple bilateral nodular hypersignals within the white matter
in connection with leukoaraïosis lesions.
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for the same subject. For all patients, the TAC revealed an
initial rapid accumulation of radioactivity in the injured
tissue, with a peak observed at 5 min post-injection (pi),
followed by a gradual cerebral clearance from 10 to
20 min pi to the end of the PET acquisition. For the two
reference regions, lower binding values of 18 F-DPA-714
were observed, with a maximum uptake at 5 min pi
followed by two decreased phases from 5 to 20 min pi and
from 10 to 20 min pi to the end of the acquisition.
Moreover, the binding of 18 F-DPA-714 was lower for
the contralateral region than for the cerebellum. For
all subjects, the 18 F-DPA-714 uptake in the infarcted
tissue remained higher than that observed for the other
two regions during the entire acquisition.
Using the two reference regions at 40 and 80 min
pi, the ratios obtained for the nine patients are pre-
sented in Table 2. The ratios using the mean activ-
ities were higher, although they were significantly
different only at 40 min pi, when the contralateral
VOI was used as the reference region, compared with
the ratios using the cerebellum (IT/CL = 1.78 ± 0.31 andFigure 2 TACs of 18 F-DPA-714 binding on the injured tissue
(IT), contralateral (CL) normal tissue and ipsilateral cerebellum.IT/Cerebellum = 1.55 ± 0.21 at 40 min, p = 0.020; IT/CL =
1.99 ± 0.56 and IT/Cerebellum = 1.79 ± 0.40 at 80 min
pi, p = 0.155 respectively). Using the maximal activity
calculated for each VOI, the ratios were also higher,
however not significantly different, when using contra-
lateral VOI (IT/CL = 2.05 ± 0.54 and IT/Cerebellum =
2.02 ± 0.64 at 40 min, p = 0.911; IT/CL = 2.44 ± 0.72
and IT/Cerebellum= 2.19 ± 0.54 at 80 min pi, p = 0.164,
respectively).
The median lesion volume estimated by MRI was
13.1 cm3 [range 0.7 (subject 7) to 190 cm3 (subject 3)].
There was no statistically significant relationship between
this volume and the 18 F-DPA-714 uptake, according to
Spearman's test (p = 0.24). However, a strong correlation
was observed between the lesion volume estimated by
MRI and the VOI volume used to calculate the activity
concentration (r = 0.95 end p = 0.0003, Spearman's test).
Discussion
In this study, all imaging scans were performed within
12.6 ± 2.7 days after the ictus. Studies performed with
the reference TSPO radioligand 11C-PK11195 in stroke
patients indicated that the binding became significant a
few days after the stroke onset, subsequently increased
in approximately 1 week, and declined after 3 to 4 weeks
[18,19,29]. A more recent study with 11C-PK11195,
conducted 2 to 3 weeks post-stroke in a group of 18
subjects confirmed the local activation of microglia
with increased radioligand uptake in the infarcted
area [23]. Moreover, activation in the peri-infarct area
appears to be more intense than in the core [30]. The
value of our study is that it demonstrates the ability of a
TSPO fluorine radioligand to map inflammatory process,
in both the infarct and the surrounding surviving tissues.
Indeed, one of the main difficulties in validating new ra-
diopharmaceuticals as biomarkers of neuroinflammation
lies in ruling out the possibility of non-specific binding,
particularly passive leakage through a damaged BBB, as
Figure 3 Ratio values calculated between injured tissue and two
reference regions (contralateral (CL) and ipsilateral cerebellum).
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monocytes/macrophages within the brain parenchyma.
We observed that the increased uptake of 18 F-DPA-714
on PET images differed, even if very moderately, from the
MRI gadolinium-enhanced regions, and was not limited
to the infarct tissue with BBB breakdown; it also included
non-infarcted cerebral tissue. This finding most likely
reflects the activation of microglia with an increase in
TSPO expression at the periphery of the necrotic lesion.
On the other hand, we cannot forget that the PET spatial
resolution is lower than that of the MRI's.
Moreover, the radiotracer uptake was not correlated
with the infarct volume measured by MRI. This point is in
accordance with a previous USPIO MRI study performed
in subacute stroke patients demonstrating that the extent
of the inflammatory response after stroke was unrelated to
the lesion volume [31].Table 2 Volumes (cm3) of infarcted region and VOIs and indiv
Patient Infarct volume VOI volume 40 min post-injection
(cm3) (cm3) IT/CL IT/Ipsila
MRI PET Mean Max Mean
1 108 93.0 2.03 2.75 1.70
2 16 6.0 1.14 1.08 1.26
3 190 163.8 2.09 2.11 159
4 13.1 17.3 2.10 2.61 1.80
5 34.6 32.3 1.93 2.14 1.55
6 3.4 3.5 1.54 1.84 1.17
7 0.7 0.73 1.83 1.68 1.73
8 12.9 13.7 1.73 2.54 1.67
9 1.6 1.8 1.66 1.67 1.48
Mean 1.78 2.05 1.55
SD 0.31 0.54 0.21
For each VOI, mean activity and maximal (Max) activity were used. The mean and s
were calculated between the injured tissue (IT, necrotic and inflammatory) and theTo our knowledge, only one study has compared two
different TSPO radioligands in post-stroke patients
(i.e., vinpocetine and PK11195, both labelled with
carbon-11) [32]. The authors compared the diagnostic
potential of these radioligands to visualise activated
microglia in four post-stroke patients. They observed
that the binding potential for 11C-vinpocetine was
greater than that obtained for 11C-PK11195 in all evalu-
ated regions, but the differences did not reach significance.
11C-vinpocetine binding potential was greater in the
peri-infarcted zone than in the ischaemic core, but the
difference did not prove to be significant [32,33].
However, a direct comparison between 18 F-DPA-714 and
11C-PK11195 labelling, on a model of cerebral ischemia in
rats, was done by Boutin et al. [34]. 18 F-DPA-714 displayed
a higher signal-to-noise ratio than 11C-PK11195, suggesting
that with the longer half-life of fluorine-18, 18 F-DPA-714
could be a good alternative for TSPO imaging.
The TACs generated for each subject showed that
18 F-DPA-714 uptake in the lesion, as well as in the
contralateral cerebral tissue and the cerebellum, reached
peak values at 5 min pi. The TACs for the injured re-
gion showed a slow decrease in binding from the max-
imum uptake to the end of the acquisition. However,
this kinetic analysis showed two decreased phases for the
other two regions: (1) a faster phase, between 5 and
approximately 20 min, and (2) a slower phase, from
20 min pi to the end of the acquisition. This evolu-
tion of the kinetics of 18 F-DPA-714 in the cerebel-
lum and in the normal cerebral tissue aligned with
that observed in a previous study performed in a
group of seven healthy volunteers [25]. Indeed, in
this previous study, we observed that the kinetics ofidual ratio values
80 min post-injection
teral cerebellum IT/CL IT/Ipsilateral cerebellum
Max Mean Max Mean Max
2.70 2.03 2.85 1.77 2.47
1.21 1.28 1.27 1.29 1.30
1.82 3.27 3.42 2.55 2.59
2.89 2.05 2.32 1.77 2.36
2.54 2.08 3.41 1.64 2.62
1.47 1.46 1.67 1.25 1.39
2.52 2.08 2.39 1.82 2.82
1.60 1.69 2.52 2.07 2.23
1.42 1.95 2.15 1.96 1.89
2.02 1.99 2.44 1.79 2.19
0.64 0.56 0.72 0.40 0.54
tandard deviation (SD) for these ratios are also indicated. Individual ratio values
two reference regions, contralateral (CL) and ipsilateral cerebellum.
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and the cerebellum.
On the other hand, stroke patients may show remote
metabolic changes in the cerebellum resulting from
diaschisis [25,35]. Although microglial changes, as a
consequence of cerebellar diaschisis, are not known,
we have chosen to take into account only the cerebellar
hemisphere ipsilateral to the stroke to define the reference
region.
The evolution of the 18 F-DPA-714 uptake in humans
differed from that reported by Martin et al. in an
ischemia model in rats [36]. The authors showed that
the 18 F-DPA-714 uptake in the lesion reached a peak
value at 30 min and remained stable until the end of
the acquisition. In our study, we observed an earlier
peak at 5 min pi followed by a slower decrease.
We also demonstrated that the binding ratio of 18 F-DPA-
714 was higher when the contralateral VOI was used
as a reference region, compared to when the cerebellum
was used as a reference region. Several authors have
previously documented the fact that the cerebellum in
humans was not devoid of TSPO [37] and it would
be of interest in future TSPO PET imaging studies to
focus on focal inflammation, including stroke, Rasmussen
encephalitis, epilepsy, and traumatic brain injury, and
to consider the contralateral area as a suitable and
TSPO-expression free reference tissue. Nevertheless,
Martin et al. also detected increased 18 F-DPA-714
binding in the contralateral side at 11 days after focal
cerebral ischemia in rats. They concluded that this
finding was probably due to different mechanisms re-
lated to the expansion of infarction, such as spreading
depression [36]. Thus, the exact fraction of specific
binding to TSPO, in both the contralateral region and
the cerebellum, would have to be determined by a
blocking study requiring substantial doses of a blocking
agent, which was ethically inconsistent with the present
study. Interestingly, the ratio values calculated in the
present study between the injured tissue and the contra-
lateral region at 40 min post-18 F-DPA-714 injection,
using the mean activity values, were significantly higher
(p = 0.020, Mann-Whitney U test) than those previously
published by Gerhard et al. using 11C-PK11195, obtained
with three acquisitions from patients with the same speci-
fications (interval in the range of 6 to 20 days between
stroke ictus and PET acquisition) [18]. Although this
comparison of two separate studies should be considered
cautiously, it suggests that 18 F-DPA-714 might represent
a good fluorine-18 alternative to 11C-PK11195 for TSPO
PET imaging, with the higher ratio of ipsilateral-to-
contralateral uptake. Moreover, our results are in ac-
cordance with preclinical direct comparison of both
radiopharmaceuticals in a rodent model of focal ischemia
[34], demonstrating that 18 F-DPA-714 achieved in vivo ahigher ratio of ipsilateral uptake to contralateral uptake
than 11C-PK11195.
Several studies have demonstrated the existence of
different binder populations for 11C-PBR28, for which
approximately 10% of the population appeared to be
non-binders [38]. Owen and colleagues evidenced 3 types
of binding pattern: high-affinity binders (approximately
50%), low-affinity binders (approximately 20%) and mixed-
affinity binders (approximately 30%), related to a single-
nucleotide polymorphism (rs6971) within the human TSPO
gene [39], and they extended this finding to other PET
TSPO radioligands, including the carbon 11-radiolabelled
derivative of 18 F-DPA-714, namely, DPA-713 [40]. One
limitation of our study is that we did not directly identify
the subjects with low or high affinity for TSPO. It is
likely that 18 F-DPA-714 is also sensitive to this variable
inter-individual affinity state. Nevertheless, all patients in
our study demonstrated increased 18 F-DPA-714 uptake
by the injured tissue.
Conclusions
Our results show that the uptake of 18 F-DPA-714 occurred
not only due to the BBB breakdown, but also because of
the activation of microglia in the area surrounding the
infarct. We also showed that the kinetics of 18 F-DPA-714
differ between injured and normal tissues. The ability
to assess microglial activation in vivo may improve our
understanding of the mechanisms of neuroinflammation
in acute disorders such as stroke, and should enable
effective treatment monitoring. This study also demon-
strates that a 10 to 20 min of PET emission acquisition,
performed between 40 and 80 min pi, was able to differen-
tiate acute tissue injury from normal brain tissue.
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